Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
暂无分享,去创建一个
P. Rutgeerts | S. Hanauer | R. Enns | W. Sandborn | R. Panaccione | J. Colombel | J. Kent | P. Pollack | Ju Li | S. Schreiber | Daniel Byczkowski